Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Nine Month Period Ended April 30, 2025
(TheNewswire)
(Toronto, Ontario) – Helix BioPharma Corp. -TheNewswire - (TSX:“HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”)(“Helix” or the “Company”), a clinical-stage oncologycompany shaping a near future where today’s hard-to-treat cancersare vincible, announces the filing of the Company’s unauditedinterim financial statements as of and for the nine month period endedApril 30, 2025 (the “Financial Statements”), themanagement’s discussion and analysis (“MD&A”), andthe certifications of the Chief Executive Officer and Chief FinancialOfficer (respectively, “CEO” and “CFO”) relatingto the Financial Statements (collectively, the “Interim Filings”). The Interim Filings are available on the Company’sprofile at www.sedarplus.ca.
About Helix BioPharma
Helix BioPharma is an oncology company that innovatesfrom strength to bring near-term solutions for today’shardest-to-treat cancers. The Company’s pipeline is led by TumorDefense Breaker™ L-DOS47, a clinical-stage antibody-enzyme conjugatedesigned to prime CEACAM6-expressing tumors for increased sensitivityto therapy and augment the effectiveness of today’s front-runninganti-cancer treatments. L-DOS47 has completed Phase Ib studies innon-small cell lung cancer (NSCLC) and shares its CEACAM6-targetingfoundation with Helix’s next-generation bi-specific antibody-drugconjugates (ADCs), currently in discovery. The Company also advancestwo pre-IND candidates: (i) LEUMUNA™, an oral immune checkpointmodulator aimed at achieving durable remission in post-transplantleukemia relapse, and (ii) GEMCEDA™, a first-in-class oralgemcitabine prodrug with bioavailability on a par with IV, designed toexpand treatment options for advanced cancers.
Helix is listed on TSX (HBP), OTC PINK (HBPCD), and FWB(HBP0). For more information, pleasevisit: https://www.helixbiopharma.com/
For more information, pleasecontact:
Helix BioPharma Corp.
Bay Adelaide Centre - North Tower
40 Temperance Street, Suite 2
Toronto, ON M5H 0B4
Tel: +1 857 208 7687
Jacek Antas, Director
corporate@helixbiopharma.com
Forward-Looking Statements and Risksand Uncertainties
This news release containsforward-looking statements and information (collectively,“forward-looking statements”) within the meaning of applicableCanadian securities laws. Forward-looking statements are statementsand information that are not historical facts but instead includefinancial projections and estimates, statements regarding plans,goals, objectives, intentions and expectations with respect to theCompany’s future business, operations, research and development,including the Company’sactivities relating to DOS47, LR 09 and GEMCEDA. Forward-lookingstatements can further be identified by the use of forward-lookingterminology such as “ongoing”, “estimates”, “expects”, orthe negative thereof or any other variations thereon or comparableterminology referring to future events or results, or that events orconditions “will”, “may”, “could”, or “should” occuror be achieved, or comparable terminology referring to future eventsor results.
Forward-looking statements arenecessarily based on a number of estimates and assumptions that theCompany considered appropriate and reasonable as of the date suchinformation is given, including but not limited to the assumptionsregarding the implied benefits of the transactions. Forward-lookingstatements are subject to known and unknown risks, uncertainties, andother factors, many of which are beyond the Company’s control, thatmay cause actual results, performance or achievements to be materiallydifferent from those expressed or implied by such forward-lookingstatements, including but not limited to the risk that the Company'sassumptions on which its forward-looking statements are based may notbe accurate; the ability of the Company to capitalize on the potentialbenefits of the transactions; and the risk factors disclosed in theCompany's periodic reports publicly filed and available on its SEDAR+profile at www.sedarplus.ca. No assurance can be given that any of the events anticipated bythe forward-looking statements will transpire or occur. There is noassurance that the proposed transactions will be completed inaccordance with its terms or at all. The forward-looking statementscontained in this news release are made as of the date of thisannouncement and the Company does not assume any obligation to updateany forward-looking statement or information should those beliefs,assumptions, opinions or expectations, or other circumstances change,except as required by law.
_________________
Copyright (c) 2025 TheNewswire - All rights reserved.
